Results 11 to 20 of about 3,233,582 (249)
Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
Drugs in Context, 2018 Lipid-lowering therapy is used very commonly nowadays not only for the optimization of the lipid profile but also to reduce cardiovascular risk. However, some studies have linked the use of certain lipid-lowering agents with an increased risk for ...
Constantine E Kosmas +5 more
doaj +2 more sources
Lipid-lowering therapy: who can benefit
Vascular Health and Risk Management, 2011 Sandra J LewisNorthwest Cardiovascular Institute, Portland, OR, USAAbstract: Cardiovascular disease (CVD) is the leading cause of death in the US. Despite the decline in CVD-associated mortality rates in recent years, coronary heart disease (CHD) still ...
Lewis S
doaj +2 more sources
Alirocoumab: new perspectives of lipid-lowering therapy
Терапевтический архив, 2017 Alirocoumab (Praluent) is a fully human monoclonal antibody against proprotein covertase subtilisin/kexin type 9 (PCSK9). The data of ODYSSEY Phases II and III clinical trials demonstrate the high efficacy of alirocoumab in lowering the level of low ...
Zh D Kobalava +2 more
doaj +3 more sources
Assessment of lipid profile when using lipid-lowering therapy (statins) in patients with coronary atherosclerosis [PDF]
Рациональная фармакотерапия в кардиологии, 2015 Aim. To assess of lipid-lowering therapy with statins in very high cardiovascular risk patients admitted to hospital for coronary angiography and analyze lipid profiles depending on the intensity of lipid-lowering therapy. Material and methods.
N. E. Gavrilova +4 more
doaj +4 more sources
Three-year dynamics and unsolved problems of lipid-lowering therapy [PDF]
Рациональная фармакотерапия в кардиологии, 2015 Aim. To study the lipid-lowering therapy, the adequacy of its control, as well as the awareness of patients at a high cardiovascular risk of atherosclerosis problems and the dynamics of these parameters in 3 years. Material and methods.
V. A. Sergeeva
doaj +4 more sources
Combined lipid-lowering therapy: choosing strategy and tactics [PDF]
Кардиоваскулярная терапия и профилактика, 2010 Achieving target levels of low-density lipoprotein cholesterol (LDL-CH) with lipid-lowering therapy is the main component of the complex cardiovascular risk reduction, according to the Russian and international clinical guidelines.
N. A. Koziolova
doaj +1 more source
MODERN ASPECTS OF LIPID LOWERING THERAPY: FOCUS ON INFLAMMATION [PDF]
Медицинский совет, 2016 Lipid lowering therapy with statin use is one of the most important components in therapy of patients with lipid exchange disturbances. Great meaning is attributed not only to lipid-modifying but to the anti-inflammatory effect at their application ...
I. A. LIBOV +2 more
doaj +2 more sources
Lipid-lowering therapy and percutaneous coronary interventions. [PDF]
, 2021 Although technological and procedural advances have resulted in substantial improvements in clinical outcomes following percutaneous coronary interventions (PCI), recurrent coronary events may occur despite achieving optimal procedural results.
Mach, François +2 more
core +1 more source
BMC Cardiovascular Disorders, 2020 Background Cardiovascular disease is the leading cause of morbidity and mortality with incidence rates of 5–10 per 1000 person-years, according to primary prevention studies.
Hsin-Yin Hsu +4 more
doaj +1 more source
Actual issues of lipid centers’ operation in Russian Federation
Кардиоваскулярная терапия и профилактика, 2021 .
S. Boytsov +10 more
doaj +1 more source